Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13028616 | 0.93 | CYP1A2 (0.32) | — | |
| SCHEMBL799947 | 0.86 | THRA (0.31) | — | |
| SCHEMBL23240852 | 0.86 | THRA (0.31) | — | |
| SCHEMBL23329027 | 0.86 | THRA (0.31) | — | |
| SCHEMBL24449773 | 0.83 | — | — | |
| SCHEMBL17307165 | 0.81 | CYP1A2 (0.30) | — | |
| SCHEMBL28206190 | 0.80 | PSEN1 (0.33) | — | |
| SCHEMBL21907173 | 0.77 | DPP4 (0.31) | — | |
| SCHEMBL416473 | 0.76 | — | — | |
| SCHEMBL12899 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373930-A1 | AMINOIMIDAZOLE FPR2 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-23 | — | — | US | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357260-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-11718616-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718616-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-7741336-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-7674796-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-7645789-B2 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-12 | — | — | US | disclosed |
| US-7615651-B2 | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof | PFIZER INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
| US-20080182840-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC | 2008-07-31 | — | — | US | disclosed |
| US-20080167371-A1 | Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof | PFIZER INC. | 2008-07-10 | — | — | US | disclosed |
| US-7351712-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718616-B2 | JAK kinase inhibitor compounds for treatment of respiratory disease | JAK1, JAK2, JAK3 | PDE8B 1145/4885 |
| US-20080182840-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | TYMS, TYMP, DPYD | PDE8B 4590/4885 |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | PDE8B 1992/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | PDE8B 1500/4885 |
| US-20230357260-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | TGFB1, TGFB2, TGFBR1 | PDE8B 628/4885 |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | CFTR, ABCB1, ABCB11 | PDE8B 1320/4885 |
| US-20080167371-A1 | Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | PDE8B 2162/4885 |
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | PDE8B 803/4885 |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | CFTR, ABCD3, ABCC2 | PDE8B 2628/4885 |
| US-20230373930-A1 | AMINOIMIDAZOLE FPR2 AGONISTS | FPR2, FPR1, FPR3 | PDE8B 2594/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | PDE8B 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.